GALVUS NOVARTIS PDF

Novartis’ Galvus (vildagliptin) is a member of a new class of oral antidiabetic agents known as dipeptidyl peptidase IV inhibitors (DPP-IV) inhibitors or ‘incretin . Galvus Approval Status. FDA Approved: No Brand name: Galvus Generic name: vildagliptin. Previous Name: LAF Company: Novartis Pharmaceuticals. Vildagliptin is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl The European Medicines Agency has also approved a combination of vildagliptin and metformin, vildagliptin/metformin (Eucreas by Novartis) as an oral.

Author: Vudogami Gujas
Country: Senegal
Language: English (Spanish)
Genre: Relationship
Published (Last): 26 March 2017
Pages: 94
PDF File Size: 14.40 Mb
ePub File Size: 10.13 Mb
ISBN: 950-2-46773-563-7
Downloads: 87300
Price: Free* [*Free Regsitration Required]
Uploader: Tygolrajas

Desvenlafaxine The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Vildagliptin.

Galvus 50 mg Tablets

The therapeutic efficacy of Vildagliptin can be increased when used in combination with Clofenamide. When used in combination with a sulphonylurea, a lower dose of the sulphonylurea may be considered to reduce the risk of hypoglycaemia.

Sirolimus The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Sirolimus. The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Indinavir. Escitalopram The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Vildagliptin. The risk or severity of angioedema can be increased when Rescinnamine is combined with Vildagliptin. Ritanserin The risk or severity of hypoglycemia can be increased when Ritanserin is combined with Vildagliptin.

Vildagliptin – DrugBank

Tipranavir The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Tipranavir. By raising GLP-1 levels the drug also enhances the sensitivity of alpha cells to glucose, resulting in more glucose-appropriate glucagon secretion. The therapeutic efficacy of Vildagliptin can be increased when used in combination with Sitafloxacin.

  EL DESPRECIO DE ALBERTO MORAVIA PDF

In patients with severe renal impairment, vildagliptin significantly decreased HbA 1c compared with placebo difference of Skin disorders Skin lesions, including blistering and ulceration have been reported in extremities of monkeys in non-clinical toxicology studies see section 5. Diflunisal Diflunisal may increase the hypoglycemic activities of Vildagliptin. In other projects Wikimedia Commons.

Glisoxepide Vildagliptin may increase the hypoglycemic activities of Glisoxepide. Cyclobenzaprine Cyclobenzaprine may decrease the hypoglycemic activities of Vildagliptin. The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Fluprednidene.

If a dose of Galvus is missed, it should be taken as soon as the patient remembers. Oxandrolone Oxandrolone may increase the hypoglycemic activities of Vildagliptin. Chlorthalidone The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Chlorthalidone. The risk or severity of angioedema can be increased when Fosinopril is combined with Vildagliptin.

In controlled clinical trials using vildagliptin 50 mg twice daily in combination with insulin, with or without concomitant metformin, the talvus incidence of withdrawals due to adverse reactions was 0. The therapeutic efficacy of Vildagliptin can be increased when used in combination with Zonisamide.

Glycodiazine The therapeutic efficacy of Vildagliptin can be increased when used in combination with Glycodiazine. The risk or severity of hypoglycemia can be increased when Agmatine is combined with Vildagliptin.

The therapeutic efficacy of Vildagliptin can novatris decreased when used in combination with Atazanavir. The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Meprednisone. Publication details Marketing-authorisation holder Novartis Europharm Limited. The potential risk for humans is unknown. Fish oil The risk or severity of hypoglycemia can be increased when Fish oil is combined with Vildagliptin.

  LM7905 DATASHEET PDF

The risk or severity of hypoglycemia can be increased when Vildagliptin is combined with Voglibose. The risk or severity of hypoglycemia can be increased when Indalpine is combined with Vildagliptin. Saprisartan The risk or severity of angioedema can be increased when Saprisartan is combined with Vildagliptin.

Icandra (previously Vildagliptin / metformin hydrochloride Novartis)

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Rare cases of hepatoxicity have been reported. Isocarboxazid Isocarboxazid may increase the hypoglycemic activities of Vildagliptin. The Pharmaceutical JournalVol. Emopamil Falvus risk or severity of hypoglycemia can be increased when Emopamil is combined with Vildagliptin. The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Octreotide.

The most common side effects with Icandra seen in more than 1 patient in 10 are nausea feeling sickvomiting, diarrhoea, abdominal tummy pain and loss of appetite.

Have your say For commenting, please login or register as a user and agree to our Community Guidelines.